FDA’s final guidance on expedited programs for drugs and biologics takes a more welcoming approach to the use of accelerated approval in some acute disease settings than did an earlier draft version of the document.
The final guidance, “Expedited Programs for Serious Conditions – Drugs and Biologics,” suggests the accelerated approval pathway may allow for smaller studies in some acute conditions than would...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?